Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Altimmune, Inc.NASDAQ: ALT

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 98.8% from a year ago

Cash & equivalents stood at $97.6M at the end of Q1 FY2026, up 98.8% from a year earlier and up 123.0% from the prior quarter. Over 3 fiscal years it compounded at -26.7% a year.

Context

  • Cash & equivalents amounted to 29.1% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +98.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$97.6M+123.0% QoQ
Last fiscal yearDec 2025
$43.76M+18.5% YoY
Year agoMar 2025
$49.1M+98.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+98.8%——
1 year+18.5%——
3-year CAGR-26.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
43.76M USD
Year-over-year change
+18.5%
4-year CAGR
-30.8%

Cash & Equivalents vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +98.8% is the highest of 9, against a peer median of +1.9%.
  • Cash & equivalents amounts to 29.1% of total assets for ALT, versus a peer median of 23.0%.
ALT Competitors
Cash & Equivalents for ALT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VIRVir Biotechnology, Inc.Mar 2026$276.09M USD+0.9%-34.9%26.9%
GPCRStructure Therapeutics Inc.Jun 2026$272.64M USD+85.4%+212.9%19.1%
IVAInventiva S.A.Dec 2025€99.27M EUR+2.8%+4.6%39.9%
ALTAltimmune, Inc.Mar 2026$97.6M USD+98.8%-26.7%29.1%
BMEABiomea Fusion, Inc.Mar 2026$44.69M USD+24.6%-20.7%96.4%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$34.93M USD-42.0%-9.8%11.1%
ASMBAssembly Biosciences, Inc.Mar 2026$31.12M USD+32.9%+3.7%13.2%
ABUSArbutus Biopharma CorporationMar 2026$23.71M USD-36.1%-16.4%8.6%
INDPIndaptus Therapeutics, Inc.Mar 2026$1.5M USD-61.5%-4.0%68.7%
Peer median (excluding ALT) —+1.9%-6.9%23.0%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents190.3M111.1M135.12M36.93M43.76M
Short-term Investments073.78M62.7M94.97M229.7M
Net Receivables5.84M2.54M4.85M3.12M1.74M
Inventory00000
Other Current Assets33.31K5.39M6.96M2.25M3M
Total Current Assets204.13M192.81M209.63M137.25M278.19M
Property, Plant & Equipment (Net)1.45M1.08M651K413K312K
Goodwill00000
Intangible Assets12.42M12.42M000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets872K615K363K1.64M1.43M
Total Non-current Assets14.74M14.12M1.01M2.05M1.74M
Total Assets218.87M206.93M210.64M139.31M279.93M
Account Payables2.03M4.8M2.07M211K2.72M
Short-term Debt00000
Tax Payables01.17M000
Deferred Revenue00000
Other Current Liabilities6.09M0000
Total Current Liabilities18.28M17.05M12.14M10.47M15M
Long-term Debt000034.29M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0000160K
Other Non-current Liabilities330K3.91M4.22M3.93M4.45M
Total Non-current Liabilities1.45M4.58M4.4M5.33M40.04M
Total Liabilities19.73M21.64M16.54M15.8M55.04M
Common Stock4K5K7K7K11K
Retained Earnings(293.17M)(377.88M)(466.33M)(561.39M)(649.48M)
Accumulated OCI(5.04M)(5.23M)(5M)(4.97M)(4.93M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity199.14M185.29M194.1M123.51M224.89M
Total Debt1.54M1.12M671K1.68M35.69M
Net Debt(188.77M)(109.97M)(134.45M)(35.25M)(8.07M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.